Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies.
Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ. · 2016
Read Alpha-synuclein RT-QuIC in the CSF of patients with alpha-synucleinopathies. by Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5048391.txt.
Introduction
Graham Fairfoul and a large co-author group test spinal fluid for Parkinson's-type diseases in the Annals of Clinical and Translational Neurology in 2016. Parkinson's disease and dementia with Lewy bodies are driven by clumping of the protein alpha-synuclein, yet early diagnosis is unreliable. Their test, called RT-QuIC, exploits the clumping itself: a trace of abnormal protein in spinal fluid seeds runaway clumping of fresh protein in a tube, which a dye then reveals.
The test caught ninety-two percent of dementia with Lewy bodies cases and ninety-five percent of Parkinson's cases, while every Alzheimer and control sample stayed negative. Diseases driven by the rival tau protein also tested negative, which sharpens the test's aim. Three people with a sleep disorder that often precedes these diseases already tested positive, hinting the test could flag disease before symptoms. Larger follow-up studies are the stated next step.
Catalog record
| CREATOR | Fairfoul G, McGuire LI, Pal S, Ironside JW, Neumann J, Christie S, Joachim C, Esiri M, Evetts SG, Rolinski M, Baig F, Ruffmann C, Wade-Martins R, Hu MT, Parkkinen L, Green AJ. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies By Graham Fairfoul, Lynne I. McGuire, Suvankar Pal, James W. Ironside, Juliane Neumann, Sharon Christie, Catherine Joachim, Margaret Esiri, Samuel G. Evetts, Michal Rolinski, Fahd Baig, Claudio Ruffmann Published in: Annals of Clinical and Translational Neurology DOI: 10.1002/acn3.338 ABSTRACT Abstract We have developed a novel real‐time quaking‐induced conversion RT‐QuIC‐based assay to detect alpha‐synuclein aggregation in brain and cerebrospinal fluid from dementia with Lewy bodies and Parkinson's disease patients. This assay can detect alpha‐synuclein aggregation in Dementia with Lewy bodies and Parkinson's disease cerebrospinal fluid with sensitivities of 92% and 95%, respectively, and with an overall specificity of 100% when compared to Alzheimer and control cerebrospinal fluid. Patients with neuropathologically confirmed tauopathies (progressive supranuclear palsy; corticobasal degeneration) gave negative results. These results suggest that RT‐QuiC analysis of cerebrospinal fluid is potentially useful for the early clinical assessment of patients with alpha‐synucleinopathies. INTRODUCTION Alpha‐synuclein (a‐syn) is well conserved, small acidic protein of 140 amino acids, and a molecular weight of 19 kDa that is encoded by the SNCA gene located on chromosome 4.1 It is located in high concentration in the presynaptic nerve terminals within the central nervous system where it plays a role in synaptic vesicle biology.2 The synucleinopathies are a set of neurodegenerative disorders associated with the deposition of fibrillary aggregates of a‐syn within selective populations of neurons and glia. These deposits can be found within neuronal soma as Lewy bodies (LB) or in dystrophic neurites in diseases such as Parkinson's disease (PD) or dementia with Lewy bodies (DLB), or in glial cytoplasmic inclusions in multiple system atrophy (MSA).3 The presence of a‐syn has been detected in biological fluids such as cerebrospinal fluid (CSF)4 and serum.5 The measurement of a‐syn concentrations in CSF by ELISAs has been proposed as a biomarker for a‐syn‐related disorders. However, despite many studies showing a reduction in CSF a‐syn levels in PD and in DLB,4, 6 overall results are not consistent.7 Even in those studies where a reduction in CSF a‐syn has been demonstrated, the differences are small8 and there is considerable overlap within patient groups and between patient and control groups. In addition the standardization of CSF a‐syn measurement between laboratories has proven difficult.9 The aggregation properties of a‐syn have recently been compared to prion protein, the aggregation of which causes transmissible spongiform encephalopathies (TSEs).10 Indeed, there is much discussion in current literature as to whether the alpha‐synucleinopathies are actually prion‐like diseases.11 A recently described technique called real‐time quaking‐induced conversion (RT‐QuIC), which exploits the ability of prion protein to induce self‐aggregation, has been used to develop a diagnostic CSF test for sporadic Creutzfeldt–Jakob disease (sCJD), the most common human form of TSE.12 Using our expertize in RT‐QuIC,12 we have developed and tested a similar assay for the detection of a‐syn in CSF. MATERIALS AND METHODS Real‐time quaking induced aggregation for alpha‐synuclein The RT‐QuiC reaction buffer (RB) was composed of 100 mmol/L phosphate buffer (pH 8.2), 10 μmol/L thioflavin T (ThT), and 0.1 mg/mL human recombinant full‐length (1–140 aa) alpha‐synuclein (Stratech, Cambridge, UK). Each well of a black 96‐well plate with a clear bottom (Nalgene Nunc International, Fisher Scientific Ltd, Loughborough, UK) contained 98 μL, 90 μL, or 85 μL RB (depending on volume of seed added) and 37 ± 3 mg of 0.5 mm zirconium/silica beads (Thistle Scientific Ltd, Glasgow, UK). Reactions were seeded with 2 μL of working strength brain homogenate, 5 μL, 10 μL or 15 μL, of undiluted CSF to a final reaction volume of 100 μL. The plates were sealed with a plate sealer film (Fisher Scientific Ltd) and incubated in a BMG OPTIMA FluoSTAR plate reader at 30°C for 120 h with intermittent shaking cycles: double orbital with 1 min shake (200 rpm), 14 min rest. ThT fluorescence measurements (450 nm excitation and 480 nm emission) were taken every 15 min. Each sample was run in duplicate, allowing two negative control samples (reactions seeded with SD and AD brain homogenate), one positive control (reaction seeded with DLB brain homogenate), an unseeded reaction, and 44 CSF samples to be tested on one plate. Patient groups Initial phase of CSF RT‐QuIC development was carried out on 99 CSF samples obtained from the OPTIMA cohort (Oxford Project to Investigate Memory and Ageing) with clinically and neuropathologically confirmed diagnosis of pure DLB (n = 12), PD (n = 2), progressive supranuclear palsy (PSP) (n = 2), corticobasal degeneration (n = 3), DLB with AD pathology (n = 17), AD with incidental LBs (n = 13), pure AD (n = 30), and controls (n = 20). OPTIMA initiated in 1988, is a prospective, longitudinal clinico‐pathological study of dementia and aging including CSF collection at multiple time points during clinical follow‐up. All clinical and pathological protocols have been described in detail13 and were approved by the local ethics committee and participants provided informed consent prior to enrollment. The validation phase of RT‐QuIC was carried out on CSF samples (20 PD, 15 controls, and 3 at‐risk) obtained from the Oxford Discovery cohort (http://opdc.medsci.ox.ac.uk) which is one of the largest, clinically best‐characterized longitudinal PD cohorts to date. Full clinical details of this cohort have been described previously.14 In brief, patients with idiopathic PD diagnosed within 3.5 years according to UK PD Society Brain Bank diagnostic criteria15 were recruited between September 2010 and September 2014 from a 2.9 million population (ethics study 10/H0505/71). Mean disease duration among 20 PD patients was 1.6 ± 1.1 years (range 0.1–3.2 years) and Hoehn and Yahr stage 1.9 ± 0.4 (range: 1–3, maximum possible score 5). The control population was recruited from spouses and friends of patients taking part in the study, as well as the general public. The at‐risk group comprised patients with REM sleep behavior confirmed on overnight polysomnography,16 80% of which have shown to develop Lewy body disorder over time.17 Demographic information is given in Table 1. [Table: Patient demographic information for the Optima and Discovery patients investigated] Brain homogenates Brain tissue was provided by the MRC Brain Bank in the NCJDRSU (ethical license 11/ES/0022). All tissue was frozen at −80°C within 2 h of being sampled and stored at −80°C prior to analysis. Brain tissues had been stored between 2 and 18 years prior to use. Frontal cortex tissue was taken from patients with Alzheimer's disease (AD), sporadic Creutzfeldt–Jakob disease (sCJD), and diffuse Lewy body dementia (DLB). In addition, frontal cortex was obtained from individuals without neurodegenerative disease from the MRC Sudden Death Brain and Tissue Bank (Sudden Death [SD] controls). Both frontal cortex and substantia nigra tissue was obtained from patients with mixed AD/DLB, mixed sCJD/DLB, and mixed AD/PD. All cases used had been examined histologically and the diagnosis reached using internationally accepted criteria.18 Initial 10% w/v brain homogenates were prepared using phosphate‐buffered saline (PBS) containing 1 mmol/L EDTA, 150 mmol/L NaCl, 0.5% Triton X, and complete protease inhibitor cocktail from Roche. Subsequent working strength BHs were prepared by diluting the above 1:20,000 with PBS. Cerebrospinal fluid samples CSF was drawn from patients by lumbar puncture and samples with visible red color were excluded to avoid blood contamination. A total quantity of 15 mL of CSF was collected in 20 mL polypropylene tubes and samples were stored on